The public issue is entirely an offer-for-sale (OFS) of up to 21.7 million shares by the promoters and other shareholders to the tune of around ₹1,800 crore, said bankers. The company operates under the “Blue Jet” brand offering niche products targeted at innovator pharmaceutical companies and multinational generic pharmaceutical companies.
Nilesh Shah says China’s $1 trillion trade surplus is built on an undervalued Yuan, not just on innovation and competitiveness
Kotak MF’s Nilesh Shah says China’s trade surplus topping $1 trillion in 11 months is not just due to innovation and competitiveness, but also a
December 9, 2025